Subcutaneous Treprostinil Improves Surgical Candidacy for Next Stage Palliation in Single Ventricle Patients With High-Risk Hemodynamics.

MLA

Sullivan, Rachel T., et al. “Subcutaneous Treprostinil Improves Surgical Candidacy for Next Stage Palliation in Single Ventricle Patients With High-Risk Hemodynamics.” Seminars in Thoracic & Cardiovascular Surgery, vol. 35, no. 4, Winter 2023, pp. 733–43. EBSCOhost, https://doi.org/10.1053/j.semtcvs.2022.07.011.

APA

Sullivan, R. T., Handler, S. S., Feinstein, J. A., Ogawa, M., Liu, E., Ma, M., Hopper, R. K., Norris, J., Hollander, S. A., & Chen, S. (2023). Subcutaneous Treprostinil Improves Surgical Candidacy for Next Stage Palliation in Single Ventricle Patients With High-Risk Hemodynamics. Seminars in Thoracic & Cardiovascular Surgery, 35(4), 733–743. https://doi.org/10.1053/j.semtcvs.2022.07.011

Chicago

Sullivan, Rachel T., Stephanie S. Handler, Jeffrey A. Feinstein, Michelle Ogawa, Esther Liu, Michael Ma, Rachel K. Hopper, Jana Norris, Seth A. Hollander, and Sharon Chen. 2023. “Subcutaneous Treprostinil Improves Surgical Candidacy for Next Stage Palliation in Single Ventricle Patients With High-Risk Hemodynamics.” Seminars in Thoracic & Cardiovascular Surgery 35 (4): 733–43. doi:10.1053/j.semtcvs.2022.07.011.